226 related articles for article (PubMed ID: 17125917)
1. Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation.
Elagib KE; Goldfarb AN
Cancer Lett; 2007 Jun; 251(2):179-86. PubMed ID: 17125917
[TBL] [Abstract][Full Text] [Related]
2. [Advances on pathogenesis research of acute myeloid leukemia with t(8;21)-- review].
Zeng HM; Guo Y; Zhu XF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1632-7. PubMed ID: 21176386
[TBL] [Abstract][Full Text] [Related]
3. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
4. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation.
de Guzman CG; Warren AJ; Zhang Z; Gartland L; Erickson P; Drabkin H; Hiebert SW; Klug CA
Mol Cell Biol; 2002 Aug; 22(15):5506-17. PubMed ID: 12101243
[TBL] [Abstract][Full Text] [Related]
6. E protein silencing by the leukemogenic AML1-ETO fusion protein.
Zhang J; Kalkum M; Yamamura S; Chait BT; Roeder RG
Science; 2004 Aug; 305(5688):1286-9. PubMed ID: 15333839
[TBL] [Abstract][Full Text] [Related]
7. Definition of a small core transcriptional circuit regulated by AML1-ETO.
Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
[TBL] [Abstract][Full Text] [Related]
8. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
[TBL] [Abstract][Full Text] [Related]
9. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.
Nishida S; Hosen N; Shirakata T; Kanato K; Yanagihara M; Nakatsuka S; Hoshida Y; Nakazawa T; Harada Y; Tatsumi N; Tsuboi A; Kawakami M; Oka Y; Oji Y; Aozasa K; Kawase I; Sugiyama H
Blood; 2006 Apr; 107(8):3303-12. PubMed ID: 16380455
[TBL] [Abstract][Full Text] [Related]
10. The ETO domain is necessary for the developmental abnormalities associated with AML1-ETO expression in the hematopoietic stem cell compartment in vivo.
de Guzman CG; Johnson A; Klug CA
Blood Cells Mol Dis; 2003; 30(2):201-6. PubMed ID: 12732184
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of CD200R1 in lineage-negative leukemic cells is characteristic of AML1-ETO-positive leukemia in mice.
Kagiyama Y; Kitaura J; Togami K; Uchida T; Inoue D; Matsukawa T; Izawa K; Kawabata KC; Komeno Y; Oki T; Nakahara F; Sato K; Aburatani H; Kitamura T
Int J Hematol; 2012 Nov; 96(5):638-48. PubMed ID: 23097187
[TBL] [Abstract][Full Text] [Related]
12. AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression.
Yeh JR; Munson KM; Chao YL; Peterson QP; Macrae CA; Peterson RT
Development; 2008 Jan; 135(2):401-10. PubMed ID: 18156164
[TBL] [Abstract][Full Text] [Related]
13. A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO.
Osman D; Gobert V; Ponthan F; Heidenreich O; Haenlin M; Waltzer L
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12043-8. PubMed ID: 19581587
[TBL] [Abstract][Full Text] [Related]
14. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity.
Lu Y; Peng ZG; Yuan TT; Yin QQ; Xia L; Chen GQ
Leukemia; 2008 Feb; 22(2):378-86. PubMed ID: 17989718
[TBL] [Abstract][Full Text] [Related]
15. Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia.
Fazi F; Zardo G; Gelmetti V; Travaglini L; Ciolfi A; Di Croce L; Rosa A; Bozzoni I; Grignani F; Lo-Coco F; Pelicci PG; Nervi C
Blood; 2007 May; 109(10):4432-40. PubMed ID: 17244680
[TBL] [Abstract][Full Text] [Related]
16. AML1-ETO interacts with Sp1 and antagonizes Sp1 transactivity through RUNT domain.
Wei H; Liu X; Xiong X; Wang Y; Rao Q; Wang M; Wang J
FEBS Lett; 2008 Jun; 582(15):2167-72. PubMed ID: 18519037
[TBL] [Abstract][Full Text] [Related]
17. KRAS (G12D) cooperates with AML1/ETO to initiate a mouse model mimicking human acute myeloid leukemia.
Zhao S; Zhang Y; Sha K; Tang Q; Yang X; Yu C; Liu Z; Sun W; Cai L; Xu C; Cui S
Cell Physiol Biochem; 2014; 33(1):78-87. PubMed ID: 24480914
[TBL] [Abstract][Full Text] [Related]
18. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
Peterson LF; Lo MC; Okumura AJ; Zhang DE
Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
[TBL] [Abstract][Full Text] [Related]
19. The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.
Linggi B; Müller-Tidow C; van de Locht L; Hu M; Nip J; Serve H; Berdel WE; van der Reijden B; Quelle DE; Rowley JD; Cleveland J; Jansen JH; Pandolfi PP; Hiebert SW
Nat Med; 2002 Jul; 8(7):743-50. PubMed ID: 12091906
[TBL] [Abstract][Full Text] [Related]
20. Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells.
Nimer SD; Moore MA
Oncogene; 2004 May; 23(24):4249-54. PubMed ID: 15156180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]